Previous 10 | Next 10 |
The European Patent Office (EPO) has granted Compugen (NASDAQ: CGEN ) a new patent for the composition of COM701 or backup antibodies for the treatment of cancer. More news on: Compugen Ltd., Healthcare stocks news, Stocks on the move, Read more ...
HOLON, Israel , April 22, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted the Company a new patent for the composition of COM701 ...
Adaptimmune (NASDAQ: ADAP ) initiated with Neutral rating and $3 (17% downside risk) price target at Mizuho Securities. More news on: Adaptimmune Therapeutics plc, Autolus Therapeutics plc, Atreca, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
HOLON, Israel , April 20, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today the publication of a peer reviewed paper titled "Characterization of BAY 1905254, a novel immu...
Gainers: RCUS +49.2% . LTRPB +13.1% . CGEN +15.9% . AM +15.3% . BBBY +12.1% . More news on: Arcus Biosciences, Inc., Liberty TripAdvisor Holdings, Inc., Compugen Ltd., Stocks on the move, , Read more ...
HOLON, Israel , April 14, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701, a first-in-c...
HOLON, Israel , April 6, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in its Phase 1 clinical trial of COM902, an immuno-oncology t...
Compugen (NASDAQ: CGEN ) initiated with Buy rating and $16 (156% upside) price target at SunTrust. Shares up 9% premarket. More news on: Compugen Ltd., Incyte Corporation, NextCure, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
HOLON, Israel , March 17, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the closing of its previously announced underwritten public offering of 8,333,334 ordinary shares at a ...
Compugen (NASDAQ: CGEN ) has priced its public offering of ~8.3M ordinary shares at $9.00 per share, for expected gross proceeds of ~$75M. More news on: Compugen Ltd., Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...